---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-25-000018"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:41:00.965076+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q1 net income $866.6M on Novartis deal; guides FY revenue $650-800M

## Summary
- Net income $866.6M vs loss $91.6M YoY, driven by $986.2M upfront from Novartis PTC518 license deal.
- Total net product & royalty revenue $189.9M; DMD franchise (Translarna+Emflaza) $134M, down YoY.
- Cash, equivalents & marketable securities $2.027B as of March 31, 2025, up from $1.14B at Dec 31, 2024.
- Positive CHMP opinion for Sephience (sepiapterin) in PKU; NDA under FDA review with PDUFA July 29, 2025.
- PTC518 Phase 2 PIVOT-HD met primary endpoint of dose-dependent blood HTT lowering; plans to discuss accelerated approval.

## SEC filing metadata
- accession: 0001070081-25-000018
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/0001070081-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-25-000018
- JSON: https://secwatch.observer/filing/0001070081-25-000018.json
- Plain text: https://secwatch.observer/filing/0001070081-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.